Skip to content
PeptideAgent

Compounding pharmacies in Ohio

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

The State of Ohio Board of Pharmacy regulates compounding pharmacies in Ohio. Compounded GLP-1 limited. How to check a pharmacy's license, plus verified listings.

Ohio at a glance

503A framework
Follows the federal 503A framework
Telehealth prescribing
Regulatory: Telehealth allowed
Asynchronous prescribing
Regulatory: Async allowed
Compounded GLP-1 access
Regulatory: Compounded GLP-1 limited

Verified compounding pharmacies serving Ohio

No verified compounding pharmacies serving Ohio are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Who regulates compounding pharmacies in Ohio

The Board of Pharmacy licenses pharmacists and terminal distributors of dangerous drugs (which includes pharmacies) under ORC chapter 4729 and regulates pharmacy compounding through OAC chapter 4729:7-2 and prescriber compounding through OAC chapter 4729:7-3. On July 17, 2025 the Board issued GLP-1 compounding guidance with FAQs for licensees. It states that pharmacy and prescriber compounding of copies of tirzepatide ended February 18, 2025 and of semaglutide ended April 22, 2025; that retatrutide and cagrilintide cannot be used in compounding under federal and state law, with any inventory to be disposed of immediately; that research use only products may never be used for compounding; and that pharmacies, clinics, and outsourcing facilities in Ohio must buy all active ingredients from Ohio-licensed drug distributors. Ohio has no state bulks list beyond these positions; peptide eligibility follows the federal 503A framework. ORC 4729.54 directs the Board to license terminal distributors whether located within or outside Ohio, and OAC 4729:5-8-02 sets licensure requirements for nonresident pharmacies, including proof of a valid home-state license and the most recent inspection report. Starting February 1, 2027, amended OAC 4729:5-2-01 requires the responsible person on an Ohio terminal distributor license held by a clinic or med spa to work at least 8 hours a month at the licensed location or make a documented quarterly on-site visit (Board of Pharmacy guidance updated September 10, 2026). [1] [4] [5] [6] [7] [8] [14]

Compounded GLP-1 access in Ohio

Compounded semaglutide and tirzepatide are limited to the federal exception for documented patient specific needs because the FDA shortage allowances ended in 2025, and the Ohio Board of Pharmacy's July 2025 GLP-1 FAQs reinforce that copies of the approved products are not routinely compoundable in Ohio. Ohio's asynchronous telehealth rule makes app-based prescribing lawful, so the main constraint for Ohio patients is the pharmacy side. [3] [4] [11]

Research use only sellers in Ohio

ORC chapter 4729 restricts the sale and distribution of dangerous drugs to licensed pharmacies, distributors, and prescribers, and the Board reminds licensees to verify that sellers are licensed. Board guidance for prescriber clinics and medical spas (updated December 8, 2025) says any drug labeled for research purposes only is unlawful for a clinic or med spa to possess, even with patient consent, and must be disposed of immediately, with patients advised to stop using it. [1] [5] [12] [13]

Ohio notes on specific peptides

  • Semaglutide: Available branded by prescription, including through synchronous or asynchronous telehealth under ORC 4743.09. The Ohio Board of Pharmacy's July 2025 GLP-1 FAQs and the end of the federal grace period on April 22, 2025 leave compounded semaglutide limited to documented patient specific needs. [2] [4] [11]
  • Tirzepatide: Available branded by prescription. Compounded tirzepatide is limited to the federal patient specific exception since February 18, 2025, and the Ohio Board's GLP-1 FAQs address it directly. [4] [11]
  • Retatrutide: Investigational and not FDA approved. The Ohio Board of Pharmacy's July 17, 2025 GLP-1 guidance states that retatrutide cannot be used in compounding under federal and state law and that licensees found compounding, selling, or administering it may face discipline, including summary suspension. [4] [11]

How to check a compounding pharmacy in Ohio

  1. Search the State of Ohio Board of Pharmacy license lookup for the pharmacy by name. A pharmacy based elsewhere needs whatever license or registration Ohio requires before it ships to you. [1] [4] [5] [6] [7] [8] [14]
  2. Ask whether it operates as a 503A pharmacy or a 503B outsourcing facility, and confirm a 503B claim against FDA's outsourcing facility information (see the verification checklist).
  3. Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
  4. Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Ohio. [1] [5] [12] [13]

Common questions in Ohio

What does the Ohio Board of Pharmacy say about compounded GLP-1s?

In July 2025 the Board published GLP-1 compounding FAQs for licensees explaining how state and federal law apply after the FDA shortages ended. They treat copies of approved semaglutide and tirzepatide as no longer routinely compoundable. [4]

Is compounded semaglutide or tirzepatide still available in Ohio?

Only in limited, patient specific cases. The federal shortage allowances ended in 2025, and the Ohio Board of Pharmacy's FAQs reinforce that compounded copies are not a routine option. [4] [11]

Can an Ohio pharmacy compound retatrutide or BPC-157?

Retatrutide is an investigational drug, and the Ohio Board of Pharmacy's July 2025 GLP-1 guidance states that it cannot be used in compounding under federal and state law. BPC-157 is not yet on the final 503A bulks list, so compounding it carries regulatory risk, and Category 2 peptides cannot be compounded. [4] [9] [10]

All peptide legal questions for Ohio

Sources

  1. [1]State of Ohio Board of Pharmacy
  2. [2]Ohio Revised Code 4743.09, Telehealth services
  3. [3]Ohio Administrative Code 4731-37-01, Telehealth (State Medical Board of Ohio)
  4. [4]State of Ohio Board of Pharmacy: Compounding of GLP-1 drug products in Ohio, guidance and FAQs (issued July 17, 2025)
  5. [5]Ohio Revised Code chapter 4729, Pharmacists; dangerous drugs
  6. [6]Ohio Revised Code 4729.54, Terminal distributor licenses
  7. [7]Ohio Administrative Code 4729:5-8-02, Non-resident pharmacies: licensure
  8. [8]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
  9. [9]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B category lists)FDA
  10. [10]FDA: Pharmacy Compounding Advisory CommitteeFDA